. 2019 Jul 22;7(3):221–225. doi: 10.14218/JCTH.2019.00018

Table 4. Summary of severe adverse events during and after the treatment.

Events	n (%)	Relation to DNVr, PEG-IFN, RTV and RBV
Neutropenia	1 (0.7)	PEG-IFN, RBV, RTV, DNVr
Tuberculosis	1 (0.7)	N/A
Ventricular tachyarrhythmia	1 (0.7)	PEG-IFN, RBV
Transient ischemic attack	1 (0.7)	N/A
Acquired digital fibrokeratoma	1 (0.7)	N/A
Craniocerebral injury	1 (0.7)	Possibly not

Abbreviations: PEG-IFN, pegylated-interferon; DNVr, ritonavir-boosted danoprevir; RBV, ribavirin; RTV, ritonavir; N/A, not applicable.